Trial
NCT05461209
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Relapsed/ Refractory Multiple Myeloma
Intervention
Talquetamab
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-15